CSL Limited (ASX:CSL – Get Free Report) insider Megan Clark purchased 132 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were acquired at an average price of A$264.85 ($167.63) per share, for a total transaction of A$34,959.94 ($22,126.54).
CSL Stock Performance
The stock has a market cap of $77.43 billion, a PE ratio of 28.02, a price-to-earnings-growth ratio of 1.29 and a beta of 0.32. The company has a quick ratio of 1.68, a current ratio of 1.86 and a debt-to-equity ratio of 64.46.
CSL Increases Dividend
The business also recently disclosed a Interim dividend, which will be paid on Tuesday, April 8th. Investors of record on Tuesday, April 8th will be issued a dividend of $2.073 per share. This represents a yield of 0.81%. The ex-dividend date is Sunday, March 9th. This is an increase from CSL’s previous Interim dividend of $1.83. CSL’s dividend payout ratio (DPR) is 50.38%.
CSL Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Articles
- Five stocks we like better than CSL
- 3 Stocks to Consider Buying in October
- Tesla: 2 Reasons to Buy, 1 Reason to Run
- The Basics of Support and Resistance
- Should You Hold NVIDIA Stock for the Long Haul or Trade It?
- Where Do I Find 52-Week Highs and Lows?
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.